Document Type
Article
Publication Date
2016
Abstract
Patents have long been the most important legal assets of biotech companies. Increasingly, however, biotech firms find themselves on one side of a divide: as either traditional product companies or platform companies. Given the differences between these two types of business models, the merits of intellectual property (IP) protection vary between them. This article explores how those differences relate to biotech startups and entrepreneurs seeking to protect their inventions.
Recommended Citation
Nature Biotechnology, Vol. 34, pp. 462-65
Included in
Antitrust and Trade Regulation Commons, Intellectual Property Law Commons, Science and Technology Law Commons